Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06959511
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Neoadjuvant Treatment
  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Given by po

Study Details

To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Key Dates

Start date
Jul 22, 2025
Status verified
Jun 2026
Primary completion
Mar 1, 2028
Completion
Oct 1, 2030

Study Design

Enrollment
45 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant with Zanzalintinib Followed by Surgery
    Zanzalintinib 60 mg orally once daily on Days 1 to 28 of a 28-day cycle.

Primary Outcome Measure

Safety and adverse events [ Time Frame: From baseline until completion of neoadjuvant therapy; an average of 6 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Cleveland Clinic Taussig Cancer InstituteClevelandOhio44195
Jessica Geiger, MD
[email protected]
Jessica Geiger, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030
Mark Zafero, MD
[email protected]
713-563-9683
Mark Zafereo, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic Taussig Cancer Institute· Cleveland, OHMD Anderson Cancer Center· Houston, TX

Related Studies